热门资讯> 正文

Purple Biotech GAAP EPADS为-0.57美元

2025-08-06 19:44

Purple Biotech press release (NASDAQ:PPBT): Q2 GAAP EPADS of -$0.57.
As of June 30, 2025, Purple Biotech had cash and cash equivalents and short-term deposits of $5.6 million. The Company cash runway is expected into the third quarter of 2026.

More on Purple Biotech

Seeking Alpha’s Quant Rating on Purple Biotech
Historical earnings data for Purple Biotech
Financial information for Purple Biotech

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。